- Home
- MBOT vs KPTI Comparison
MBOT vs KPTI Comparison
Compare MBOT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | KPTI |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.7M | 172.6M |
| IPO Year | 2000 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MBOT | KPTI |
|---|---|---|
| Price | $2.38 | $8.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $7.50 | ★ $15.40 |
| AVG Volume (30 Days) | ★ 2.2M | 783.4K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $116,887.00 | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4,186.27 | $46.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.34 | $3.51 |
| 52 Week High | $4.62 | $10.99 |
Technical Indicators
Market Signals| Indicator | MBOT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 53.29 |
| Support Level | $2.34 | $5.60 |
| Resistance Level | $2.68 | $8.95 |
| Average True Range (ATR) | 0.17 | 0.78 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 55.00 | 14.95 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).